Last updated: 2026-09-06 06:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Codexis, Inc. (CDXS) operates in the INDUSTRIAL ORGANIC CHEMICALS sector and is listed on NASDAQ. The stock is currently priced at $1,46, with a market capitalization of $161,52M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,96 to $2,98. This page covers its latest market performance, valuation, price trends and company information.
$161,52M | |
$1,43 | |
$42,01 | |
$0,96 | |
$1,42 | |
666,54K | |
-- | |
-- | |
$2,98 | |
$0,96 | |
-- | |
-- |
Codexis, Inc. (CDXS) last closed at $1,42 as of 2026-09-04 23:57:00, unchanged from the previous close of $1,42.
During the latest regular trading session, CDXS traded between $0,96 and $42,01, with a volume of 666,54K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Codexis, Inc. (CDXS) moved from $1,59 to $1,46, representing a decline of 8,49% ($0,14).
The stock traded between $1,42 and $1,51 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 921,39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 24,6%
CDXS is currently trading at $1,46, placing it 24,6% of the way from its 52-week low of $0,96 to its 52-week high of $2,98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
| Industry | INDUSTRIAL ORGANIC CHEMICALS |
| Employees | 146 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Codexis, Inc. (CDXS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.